Pharmacogenetic prediction of clozapine response

被引：233
|
作者：
Arranz, MJ
Munro, J
Birkett, J
Bolonna, A
Mancama, D
Sodhi, M
Lesch, KP
Meyer, JFW
Sham, P
Collier, DA
Murray, RM
Kerwin, RW
机构：
[1] Inst Psychiat, Dept Clin Neurophysiol, London SE5 8AF, England
[2] Inst Psychiat, Dept Psychol Med, London SE5 8AF, England
[3] Univ Wurzburg, Dept Psychiat, D-97080 Wurzburg, Germany
来源：
LANCET | 2000年 / 355卷 / 9215期
关键词：
D O I：
10.1016/S0140-6736(00)02221-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We did association studies in multiple candidate genes to find the combination of polymorphisms that give the best predictive value of response to clozapine In schizophrenic patients. A combination of six polymorphisms in neurotransmitter-receptor-related genes resulted in 76.7% success in the prediction of clozapine response (p=0.0001) and a sensitivity of 95% (+/-0.04) for satisfactory response. These results will form the basis for a simple test to enhance the usefulness of clozapine in psychiatric treatment.
引用
收藏
页码：1615 / 1616
页数：2
相关论文
共 50 条
  • [41] Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression
    Islam, Farhana
    Gorbovskaya, Ilona
    Mueller, Daniel J.
    MAJOR DEPRESSIVE DISORDER: RETHINKING AND UNDERSTANDING RECENT DISCOVERIES, 2021, 1305 : 231 - 255
  • [42] PHARMACOGENETIC MARKERS FOR TOXICITY PREDICTION IN ONCOLOGICAL TREATMENT
    Lopez Fernandez, L. A.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 24 - 24
  • [43] Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm
    Jimenez-Varo, Enrique
    Canadas-Garre, Marisa
    Gutierrez-Pimentel, Maria J.
    Calleja-Hernandez, Miguel A.
    PHARMACOGENETICS AND GENOMICS, 2014, 24 (10): : 501 - 513
  • [44] Gender influence on pharmacogenetic prediction of antidepressive efficacy
    Baghai, TC
    Schüle, C
    Eser, D
    Zwanzger, P
    Ella, R
    Deiml, T
    Zill, P
    Rupprecht, R
    Bondy, B
    PHARMACOPSYCHIATRY, 2003, 36 (05) : 212 - 212
  • [45] Pharmacogenetic Modeling for Prediction of Patient Outcomes in Myeloma
    Vatsveen, T. K.
    Brenne, A-T
    Dai, H. Y.
    Waage, A.
    Sundan, A.
    Borset, M.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S103 - S104
  • [46] A pharmacogenetic test for prediction of vulnerability to tardive dyskinesia
    Segman, RH
    Goltser-Dubner, T
    Macciardi, F
    Lerer, B
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S252 - S252
  • [47] Pharmacogenetic studies of drug response in schizophrenia
    Arranz, M. J.
    Gallego, C.
    Salazar, J.
    Arias, B.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2016, 1 (01): : 79 - 91
  • [48] Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia
    Sanguesa, Estela
    Fernandez-Egea, Emilio
    Concha, Julia
    Garcia, Cristina B.
    Ribate, Maria Pilar
    BIOMEDICINES, 2024, 12 (03)
  • [49] Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review
    Merino, Diane
    Fernandez, Arnaud
    Gerard, Alexandre O.
    Ben Othman, Nouha
    Rocher, Fanny
    Askenazy, Florence
    Verstuyft, Celine
    Drici, Milou-Daniel
    Thummler, Susanne
    PHARMACEUTICALS, 2022, 15 (06)
  • [50] Characterisation of response to antidepressants in a pharmacogenetic trial
    Uher, R.
    Maier, W.
    Rietschel, M.
    Hauser, J.
    Mors, O.
    Marusic, A.
    Henigsberg, N.
    Perez, J.
    Mendlewicz, J.
    McGuffin, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S75 - S76
12345